The estimated Net Worth of Advisors Llcedelman Josephp... is at least $85.1 Millón dollars as of 25 May 2017. Advisors Josephp owns over 1,902,400 units of Amicus Therapeutics Inc stock worth over $62,504,874 and over the last 11 years Advisors sold FOLD stock worth over $22,606,643.
Advisors has made over 41 trades of the Amicus Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Advisors bought 1,902,400 units of FOLD stock worth $11,890,000 on 25 May 2017.
The largest trade Advisors's ever made was buying 4,000,000 units of Amicus Therapeutics Inc stock on 30 June 2014 worth over $14,000,000. On average, Advisors trades about 430,069 units every 34 days since 2013. As of 25 May 2017 Advisors still owns at least 5,546,129 units of Amicus Therapeutics Inc stock.
You can see the complete history of Advisors Josephp stock trades at the bottom of the page.
Over the last 17 years, insiders at Amicus Therapeutics Inc have traded over $306,740,337 worth of Amicus Therapeutics Inc stock and bought 23,821,602 units worth $176,323,212 . The most active insiders traders include Advisors Llcperceptive Life..., Peter J Barris y Plc Gsk. On average, Amicus Therapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $830,419. The most recent stock trade was executed by Bradley L Campbell on 3 September 2024, trading 7,500 units of FOLD stock currently worth $64,575.
amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g
Amicus Therapeutics Inc executives and other stock owners filed with the SEC include: